Early anti-TNF and stricture progression in esophageal CD
What is the evidence that early anti-TNF prevents progression from mucosal inflammation to fibrostenotic strictures in oesophageal CD
What is known
- Anti-TNF has the most consistent efficacy signal in upper-GI/esophageal CD, with clinical response ~70-85% and endoscopic healing ~30-50%, but data are observational. 1
- In GETAID and CREOLE cohorts early anti-TNF was associated with reduced surgery risk (OR ≈0.2-0.25) in UGI-CD, including fibrostenotic presentations. 1
- A systematic review of UGI-CD identified 11 observational studies plus post-hoc analyses of two RCTs (387 patients), and concluded that controlled data are lacking. 2
What is unknown / caveats
- Evidence is retrospective/observational; no RCT isolates stricture prevention as an endpoint
- Esophageal-specific cohorts are small single-institution series
- Surgery avoidance is used as a surrogate, not direct measurement of fibrostenotic progression
- Whether early biologic therapy truly prevents stricture occurrence versus its need for intervention remains explicitly unresolved and flagged for future prospective study.
References
- Lusetti F, Bezzio C, De Bernardi A, Puricelli M, Manes G, Saibeni S. Upper Gastrointestinal Crohn's Disease: Shedding Light on the Obscure L4 Classification Meaning. J Clin Med. 2025. PMID: 41303293.
- Chatto M, Alaskar D, Ma C, Yuan Y, Vuyyuru SK, Bessissow T, Narula N, Danese S, Peyrin-Biroulet L, Singh S, Jairath V, Sedano R. Pharmacological management of upper gastrointestinal Crohn's disease: a systematic review. J Crohns Colitis. 2025. PMID: 41148060.
For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.
⚠ Required context not in this corpus (moderate). Endoscopic balloon dilation is an established option for short (<5 cm) fibrostenotic and anastomotic Crohn's strictures, with high technical success and low complication rates (Bettenworth 2017 pooled analysis, PMID 28002130). It can defer or avoid repeat resection.
Why this matters: Presenting the choice as medical therapy versus repeat resection omits the bowel-sparing option that a suitable short stricture should be offered first.
Added by the landmark interlock. This corpus is surgical in scope and cannot admit the source paper (PMID 28002130). Not generated by the RAG.
Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.
Reviewer notes